To determine whether intranasal corticosteroids are superior to oral H1 receptor antagonists (antihistamines) in the treatment of allergic rhinitis.
The concealment of allocation was assessed following the guidelines of the Cochrane Collaboration (see Other Publications of Related Interest).Independent assessment by two reviewers.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the authors performed the data extraction.
Categorical outcomes were analysed as odds ratios and 95% confidence intervals calculated by Peto's method. Continuous outcomes were analysed as standardised mean differences, which allow the scores from different assessment scales to be combined.
Methods of synthesis
How were the studies combined? Fixed-effect models were used to obtain statistics for the overall efficacy of intranasal corticosteroids on both categorical and continuous outcomes.
How were differences between studies investigated?
Chi-squared tests were used to assess heterogeneity between studies. Subgroup analyses were conducted to identify sources of heterogeneity.
Results of the review
Sixteen studies, comprising 2267 participants were included in the review.
None of the studies included in the review separately reported drug scores or quality of life.
The effects on sneezing, total nasal symptoms, and eye symptoms were significantly heterogeneous between studies. Other combined outcomes were homogeneous between studies.
Intranasal corticosteroids produced significantly greater relief than oral antihistamines of nasal blockage (14 studies; standard mean difference (SMD) = -0.63, 95% CI: -0.73, -0.53), nasal discharge (14 studies; SMD = -0.50, 95% CI: -0.60, -0.40), sneezing (14 studies; SMD = -0.49, 95% CI: -0.59, -0.39), nasal itch (11 studies; SMD = -0.38, 95% CI: -0.49, -0.27), postnasal drip (2 studies; SMD = -0.24, 95% CI: -0.42, -0.06), and total nasal symptoms (9 studies; SMD = -0.42, 95% CI: -0.53, -0.32). Global ratings gave an odds ratio for deterioration of symptoms (2 studies; OR = 0.26, 95% CI: 0.08, 0.8). There were no significant differences between treatments for nasal discomfort (1 study) or nasal resistance (1 study).
There was no significant difference between intranasal corticosteroids and oral antihistamines on eye symptoms (11 studies).
There was significant heterogeneity in studies reporting eye symptoms (chi-squared = 32.4, p<0.0005). Stratification by intranasal corticosteroids showed that most of the heterogeneity occurred in trials with beclomethasone. Trials that used intranasal fluticasone, triamcinolone, or budesonide all showed no difference from antihistamines. Stratification by antihistamine showed significant heterogeneity in trials that used terfenadine or astemizole. Stratification by the period of data extraction showed a small homogeneous benefit from intranasal corticosteroids (SMD = -0.17, 95% CI: -0.35, -0.05) in those trials reporting eye symptoms as a single end point. However, there was significant heterogeneity (chi-squared = 20.2, p<0.0005) when eye symptoms had been averaged over the duration of the trial.
Cost information
The cost-effectiveness of intranasal corticosteroids versus oral antihistamines was assessed in 3 RCTs on the treatment of allergic rhinitis. An American study showed that if a patient used terfenadine for more than 11 to 22 days, then fluticasone was a more cost effective choice. Two cost-effectiveness analyses performed in Canada produced costeffectiveness ratios of 1: 2.5 and 1: 5.7 in favour of fluticasone versus terfenadine and loratadine respectively.
